Targeted therapy for locally advanced and/or metastatic bladder cancer;Les thérapeutiques ciblées du cancer de vessie localement avancé et/ou métastatique

Progres en Urologie

Volumn 18, Issue 7, 2008, Pages 407-417

  Wallerand, H ^a   Robert, G ^a   Bernhard, J C ^a   Ravaud, A ^b   Ferriere J M ^a  

^a HÔPITAL PELLEGRIN   (France)

^b HÔPITAL SAINT ANDRÉ   (France)

Author keywords

Molecular biology; Monoclonal antiboby; Proteine kinase inhibitor; Signal pathways; Treatment associated cancer; Urinary bladder neoplasms

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; BEVACIZUMAB; ERLOTINIB; GEFITINIB; IMMUNOSUPPRESSIVE AGENT; LONAFARNIB; MONOCLONAL ANTIBODY; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; RAPAMYCIN; TRASTUZUMAB;

BLADDER TUMOR; COMPARATIVE STUDY; DISEASE COURSE; GENE THERAPY; GENETICS; HUMAN; METASTASIS; MUTATION; RANDOMIZED CONTROLLED TRIAL; SHORT SURVEY; SIGNAL TRANSDUCTION; TARGETED GENE REPAIR;

ANGIOGENESIS INHIBITORS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; GENE THERAPY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MUTATION; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIDINES; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIGNAL TRANSDUCTION; SIROLIMUS; TARGETED GENE REPAIR; URINARY BLADDER NEOPLASMS;

EID: 46049108729     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.purol.2008.04.020     Document Type: Short Survey

References (32)

1. Amsellen-Ouazana D., Goldwasser F., Bieche I., Lidereau R., and Zerbib M. Anti-ErbB targeted therapy and urothelial tumors. Prog Urol 15 6 suppl. 1 (2005) 1229-1235
2. Chow N.H., Liu H.S., Yang H.B., Chan S.H., and Su I.J. Expression patterns of erbB receptor family in normal urothelium and transitional cell carcinoma. An immunohistochemical study. Virchows Arch 430 6 (1997) 461-466
3. Messing E.M. Growth factors and bladder cancer: clinical implications of the interactions between growth factors and their urothelial receptors. Semin Surg Oncol 8 5 (1992) 285-292
4. Nicholson R.I., Gee J.M., and Harper M.E. EGFR and cancer prognosis. Eur J Cancer 37 suppl. 4 (2001) S9-S15
5. Inoue K., Slaton J.W., Perrotte P., Davis D.W., Bruns C.J., Hicklin D.J., et al. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res 6 12 (2000) 4874-4884
6. Ranson M., Hammond L.A., Ferry D., Kris M., Tullo A., Murray P.I., et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 20 9 (2002) 2240-2250
7. ®), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6 12 (2000) 4885-4892
8. Ferreira C.G., Huisman C., and Giaccone G. Novel approaches to the treatment of non-small cell lung cancer. Crit Rev Oncol Hematol 41 1 (2002) 57-77
9. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244 4905 (1989) 707-712
10. Vollmer R.T., Humphrey P.A., Swanson P.E., Wick M.R., and Hudson M.L. Invasion of the bladder by transitional cell carcinoma: its relation to histologic grade and expression of p53, MIB-1, c-erb B-2, epidermal growth factor receptor, and Bcl-2. Cancer 82 4 (1998) 715-723
11. Albanell J., Codony-Servat J., Rojo F., Del Campo J.M., Sauleda S., Anido J., et al. Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res 61 17 (2001) 6500-6510
12. Pycha A., Grbovic M., Posch B., Schnack B., Haitel A., Heinz-Peer G., et al. Paclitaxel and carboplatin in patients with metastatic transitional cell carcinoma of the urinary tract. Urology 53 (1999) 510-515
13. ®) in patients with HER-2-overexpressing metastatic or locally advanced transitional cell carcinoma of the bladder: report on 7 patients. Eur J Cancer 42 (2006) 2660-2661
14. Hussain M.H., MacVicar G.R., Petrylak D.P., Dunn R.L., Vaishampayan U., Lara Jr. P.N., et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol 25 16 (2007) 2218-2224
15. Capon D.J., Chen E.Y., Levinson A.D., Seeburg P.H., and Goeddel D.V. Complete nucleotide sequences of the T24 human bladder carcinoma oncogene and its normal homologue. Nature 302 5903 (1983) 33-37
16. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3 1 (2003) 11-22
17. Adjei A.A., Davis J.N., Erlichman C., Svingen P.A., and Kaufmann S.H. Comparison of potential markers of farnesyltransferase inhibition. Clin Cancer Res 6 6 (2000) 2318-2325
18. Cohen-Jonathan E., Evans S.M., Koch C.J., Muschel R.J., McKenna W.G., Wu J., et al. The farnesyltransferase inhibitor L744, 832 reduces hypoxia in tumors expressing activated H-Ras. Cancer Res 61 5 (2001) 2289-2293
19. Wu X., Obata T., Khan Q., Highshaw R.A., De Vere White R., et al. The phosphatidylinositol-3 kinase pathway regulates bladder cancer cell invasion. BJU Int 93 1 (2004) 143-150
20. Bénistant C., Chapuis H., and Roche S. A specific function for phosphatidylinositol 3-kinase alpha (p85alpha-p110alpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in de novo DNA synthesis of human colon carcinoma cells. Oncogene 19 44 (2000) 5083-5090
21. Xu G., Zhang W., Bertram P., Zheng X.F., and McLeod H. Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors. Int J Oncol 24 4 (2004) 893-900
22. Mitra A.P., Datar R.H., and Cote R.J. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J Clin Oncol 4 35 (2006) 5552-5564
23. Chopin D., Capellen D., Radvanyi F., and Gattegno B. The p53 gene. Prog Urol 5 6 suppl. 1 (2005) 1338-1343
24. Kuball J., Wen S.F., Leissner J., Atkins D., Meinhardt P., Quijano E., et al. Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation. J Clin Oncol 20 4 (2002) 957-965
25. Pagliaro L.C., Keyhani A., Williams D., Woods D., Liu B., Perrotte P., et al. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy. J Clin Oncol 1 12 (2003) 2247-2253
26. Fodor I., Timiryasova T., Denes B., Yoshida J., Ruckle H., and Lilly M. Vaccinia virus mediated p53 gene therapy for bladder cancer in an orthotopic murine model. J Urol 73 2 (2005) 604-609
27. Mese H., Sasaki A., Alcalde R.E., Nakayama S., and Matsumura T. Regulation of apoptosis reduction in the cisplatin-resistant A431 cell line by Bcl-2 and CPP32. Chemotherapy 6 1 (2000) 69-76
28. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 6 3 (1996) 353-364
29. Brown N.S., Jones A., Fujiyama C., Harris A.L., and Bicknell R. Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factors. Cancer Res 60 22 (2000) 6298-6302
30. Grossfeld G.D., Ginsberg D.A., Stein J.P., Bochner B.H., Esrig D., Groshen S., et al. Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. J Natl Cancer Inst 89 3 (1997) 219-227
31. Inoue K., Chikazawa M., Fukata S., Yoshikawa C., and Shuin T. Frequent administration of angiogenesis inhibitor TNP-470 (AGM-1470) at an optimal biological dose inhibits tumor growth and metastasis of metastatic human transitional cell carcinoma in the urinary bladder. Clin Cancer Res 8 7 (2002) 2389-2398
32. Crawford R.A., Caldwell C., Iles R.K., Lowe D., Shepherd J.H., and Chard T. Prognostic significance of the Bcl-2 apoptotic family of proteins in primary and recurrent cervical cancer. Br J Cancer 78 2 (1998) 210-214